Waters Corporation $WAT Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Waters Corporation (NYSE:WAT) by 2.5% in the second quarter, Holdings Channel reports. The institutional investor owned 774,955 shares of the medical instruments supplier’s stock after selling 19,634 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Waters were worth $290,639,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Pilgrim Global Advisors LLC acquired a new position in Waters during the 2nd quarter worth $466,131,171,000. BlackRock Inc. bought a new stake in shares of Waters in the 2nd quarter worth about $3,182,191,000. Jupiter Topco LLC acquired a new stake in shares of Waters in the 2nd quarter valued at about $623,921,000. Janus Henderson Group PLC raised its stake in shares of Waters by 27.0% in the 1st quarter. Janus Henderson Group PLC now owns 1,638,772 shares of the medical instruments supplier’s stock valued at $488,028,000 after purchasing an additional 348,379 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Waters by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier’s stock worth $602,921,000 after purchasing an additional 8,590 shares during the last quarter. 94.01% of the stock is owned by institutional investors and hedge funds.

Waters Price Performance

Shares of NYSE:WAT opened at $414.94 on Tuesday. The company has a market cap of $40.77 billion, a PE ratio of 103.48, a P/E/G ratio of 2.41 and a beta of 1.19. Waters Corporation has a fifty-two week low of $282.77 and a fifty-two week high of $426.22. The firm has a 50-day simple moving average of $388.66 and a 200 day simple moving average of $349.22. The company has a quick ratio of 1.29, a current ratio of 1.86 and a debt-to-equity ratio of 0.32.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, beating analysts’ consensus estimates of $3.01 by $0.04. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.62 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%.Waters’s quarterly revenue was up 113.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.95 earnings per share. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. On average, sell-side analysts anticipate that Waters Corporation will post 14.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on WAT shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $400.00 price target on shares of Waters in a research note on Wednesday, August 5th. The Goldman Sachs Group increased their target price on Waters from $380.00 to $425.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. UBS Group lifted their target price on Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Barclays boosted their price target on Waters from $425.00 to $460.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. Finally, HSBC upped their price target on Waters from $415.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Waters has a consensus rating of “Moderate Buy” and an average target price of $424.35.

Insider Activity

In related news, Director Christopher A. Kuebler sold 3,626 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the completion of the transaction, the director owned 17,808 shares in the company, valued at $7,086,515.52. The trade was a 16.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.31% of the company’s stock.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.